David G McLeod
Overview
Explore the profile of David G McLeod including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
125
Citations
2789
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Higano C, Armstrong A, Sartor A, Vogelzang N, Kantoff P, McLeod D, et al.
Cancer
. 2019 Sep;
125(23):4172-4180.
PMID: 31483485
Background: The large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Methods: PROCEED enrolled...
12.
Crawford E, Schellhammer P, McLeod D, Moul J, Higano C, Shore N, et al.
J Urol
. 2018 May;
200(5):956-966.
PMID: 29730201
Purpose: Antiandrogens inhibit the androgen receptor and have an important role in the treatment of prostate cancer. This review provides a historical perspective on the development and clinical benefit of...
13.
Mohamed A, Xavier C, Sukumar G, Tan S, Ravindranath L, Seraj N, et al.
Cancer Res
. 2018 May;
78(13):3659-3671.
PMID: 29712692
Oncogenic activation of the ETS-related gene () by recurrent gene fusions (predominantly TMPRSS2-ERG) is one of the most validated and prevalent genomic alterations present in early stages of prostate cancer....
14.
15.
16.
Cullen J, Young D, Chen Y, Degon M, Farrell J, Sedarsky J, et al.
Eur Urol Focus
. 2017 Jul;
4(6):818-824.
PMID: 28753864
Background: ETS-related gene (ERG) oncogenic activation is the most common genomic alteration in prostate cancer (CaP) although it occurs less frequently in African American (AA) versus Caucasian (CA) patients, and...
17.
Mohamed A, Tan S, Xavier C, Katta S, Huang W, Ravindranath L, et al.
Mol Cancer Res
. 2017 Jun;
15(10):1308-1317.
PMID: 28607007
The oncogenic activation of the ETS-related gene () due to gene fusions is present in over half of prostate cancers in Western countries. Because of its high incidence and oncogenic...
18.
Rastogi A, Ali A, Tan S, Banerjee S, Chen Y, Cullen J, et al.
Genes Cancer
. 2017 Feb;
7(11-12):394-413.
PMID: 28191285
Overdiagnosis and overtreatment of prostate cancer (CaP) is attributable to widespread reliance on PSA screening in the US. This has prompted us and others to search for improved biomarkers for...
19.
20.
Petrovics G, Li H, Stumpel T, Tan S, Young D, Katta S, et al.
EBioMedicine
. 2016 Feb;
2(12):1957-64.
PMID: 26844274
Evaluation of cancer genomes in global context is of great interest in light of changing ethnic distribution of the world population. We focused our study on men of African ancestry...